Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AET Aetna	$212.70	$212.70	$166.88 ▼ $213.36	$69.64B	0.71	3.69 million shs	11.86 million shs
CVS CVS Health	$66.91 -0.3%	$64.98	$43.56 ▼ $72.51	$84.55B	0.56	10.90 million shs	5.21 million shs
GH Guardant Health	$50.57 +2.1%	$44.35	$20.14 ▼ $52.92	$6.27B	1.37	2.13 million shs	2.84 million shs
RPRX Royalty Pharma	$34.91 +1.0%	$33.08	$24.05 ▼ $35.38	$19.63B	0.48	3.62 million shs	3.96 million shs
TEM Tempus AI	$69.10 -1.4%	$58.21	$22.89 ▼ $91.45	$11.96B	N/A	7.03 million shs	10.67 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AET Aetna	0.00%	0.00%	0.00%	0.00%	0.00%
CVS CVS Health	0.00%	+0.85%	+4.98%	-0.47%	+9.66%
GH Guardant Health	0.00%	+3.16%	+26.52%	+9.70%	+68.90%
RPRX Royalty Pharma	0.00%	-1.02%	+5.50%	+3.59%	+32.94%
TEM Tempus AI	0.00%	-2.99%	+10.68%	+34.57%	+127.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AET Aetna	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVS CVS Health	4.9872 of 5 stars	3.5	4.0	3.3	3.9	2.8	3.3	3.1
GH Guardant Health	3.6769 of 5 stars	2.5	3.0	0.0	4.3	1.5	2.5	0.6
RPRX Royalty Pharma	4.8394 of 5 stars	3.6	1.0	3.3	3.7	3.6	1.7	2.5
TEM Tempus AI	1.688 of 5 stars	2.3	2.0	0.0	0.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AET Aetna	0.00	N/A	N/A	N/A
CVS CVS Health	2.95	Moderate Buy	$75.07	12.20% Upside
GH Guardant Health	3.00	Buy	$53.76	6.31% Upside
RPRX Royalty Pharma	3.25	Buy	$47.33	35.59% Upside
TEM Tempus AI	2.54	Moderate Buy	$63.42	-8.22% Downside

Current Analyst Ratings Breakdown

Latest AET, CVS, RPRX, TEM, and GH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	GH Guardant Health	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $65.00
6/2/2025	CVS CVS Health	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$82.00 ➝ $79.00
5/20/2025	TEM Tempus AI	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$48.00 ➝ $68.00
5/16/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00
5/15/2025	TEM Tempus AI	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$55.00 ➝ $70.00
5/12/2025	CVS CVS Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$82.00 ➝ $84.00
5/9/2025	TEM Tempus AI	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$60.00 ➝ $65.00
5/7/2025	TEM Tempus AI	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/6/2025	CVS CVS Health	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$76.00 ➝ $84.00
5/6/2025	GH Guardant Health	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $60.00
5/5/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AET Aetna	$60.54B	1.15	$12.44 per share	17.10	$56.70 per share	3.75
CVS CVS Health	$378.96B	0.22	$9.09 per share	7.36	$60.18 per share	1.11
GH Guardant Health	$739.02M	8.48	N/A	N/A	($1.13) per share	-44.75
RPRX Royalty Pharma	$2.26B	8.67	$4.20 per share	8.32	$17.56 per share	1.99
TEM Tempus AI	$803.32M	14.89	N/A	N/A	$0.35 per share	197.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AET Aetna	$1.90B	$9.86	21.57	17.15	1.82	5.99%	20.78%	6.22%	N/A
CVS CVS Health	$4.61B	$4.19	15.97	9.88	0.96	1.39%	10.59%	3.17%	8/6/2025 (Estimated)
GH Guardant Health	-$436.37M	-$3.39	N/A	N/A	N/A	-53.82%	-1,200.44%	-26.77%	8/6/2025 (Estimated)
RPRX Royalty Pharma	$858.98M	$1.85	18.87	7.18	1.79	48.23%	24.71%	13.87%	8/6/2025 (Estimated)
TEM Tempus AI	-$705.81M	-$7.80	N/A	N/A	N/A	-88.27%	-533.21%	-66.19%	8/5/2025 (Estimated)

Latest AET, CVS, RPRX, TEM, and GH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million
5/6/2025	Q1 2025	TEM Tempus AI	-$0.27	-$0.24	+$0.03	-$0.40	$248.13 million	$255.74 million
5/1/2025	Q1 2025	CVS CVS Health	$1.62	$2.25	+$0.63	$1.41	$93.07 billion	$94.59 billion
4/30/2025	Q1 2025	GH Guardant Health	-$0.57	-$0.49	+$0.08	-$0.77	$189.91 million	$203.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AET Aetna	$2.00	0.94%	N/A	20.28%	N/A
CVS CVS Health	$2.66	3.98%	N/A	63.48%	4 Years
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.52%	N/A	47.57%	5 Years
TEM Tempus AI	N/A	N/A	N/A	N/A	N/A

Latest AET, CVS, RPRX, TEM, and GH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	RPRX Royalty Pharma	quarterly	$0.22	2.7%	5/16/2025	5/16/2025	6/10/2025
3/20/2025	CVS CVS Health	quarterly	$0.6650	3.89%	4/22/2025	4/22/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AET Aetna	0.42	0.79	0.79
CVS CVS Health	0.77	0.82	0.63
GH Guardant Health	N/A	4.11	3.76
RPRX Royalty Pharma	0.68	1.56	1.56
TEM Tempus AI	2.45	1.71	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AET Aetna	82.34%
CVS CVS Health	80.66%
GH Guardant Health	92.60%
RPRX Royalty Pharma	54.35%
TEM Tempus AI	24.22%

Insider Ownership

Company	Insider Ownership
AET Aetna	1.21%
CVS CVS Health	1.22%
GH Guardant Health	6.10%
RPRX Royalty Pharma	18.90%
TEM Tempus AI	27.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AET Aetna	N/A	327.40 million	N/A	Optionable
CVS CVS Health	300,000	1.27 billion	1.25 billion	Optionable
GH Guardant Health	2,021	123.89 million	116.33 million	Not Optionable
RPRX Royalty Pharma	80	562.24 million	455.98 million	Optionable
TEM Tempus AI	2,400	173.12 million	125.34 million	N/A

AET, CVS, RPRX, TEM, and GH Headlines

Recent News About These Companies

Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) EVP Sells 51,317 Shares of Stock

June 20 at 4:07 AM | americanbankingnews.com

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps Sells 51,317 Shares

June 20 at 4:05 AM | marketbeat.com

SG Americas Securities LLC Has $834,000 Stock Holdings in Tempus AI, Inc. (NASDAQ:TEM)

June 20 at 3:28 AM | marketbeat.com

Tempus faces shareholder lawsuit in wake of short seller report

June 19 at 7:09 PM | chicagobusiness.com

Tempus AI (NASDAQ:TEM) Stock Price Down 1.4% - Time to Sell?

June 19 at 11:50 AM | marketbeat.com

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. (NASDAQ: TEM)

June 19 at 8:15 AM | globenewswire.com

TEMPUS AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM

June 18 at 11:02 PM | globenewswire.com

Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference

June 18 at 8:54 PM | uk.finance.yahoo.com

Securities Fraud Investigation Into Tempus AI, Inc. (TEM) Announced - Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

June 18 at 8:54 PM | tmcnet.com

Securities Fraud Investigation Into Tempus AI, Inc. (TEM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

June 18 at 6:23 PM | businesswire.com

TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 18 at 4:00 PM | globenewswire.com

Tempus AI (NASDAQ:TEM) Stock Price Up 1.2% - Time to Buy?

June 18 at 3:29 PM | marketbeat.com

INVESTOR ALERT: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead the Tempus AI Class Action Lawsuit - TEM

June 18 at 2:39 PM | prnewswire.com

TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM

June 18 at 12:19 PM | globenewswire.com

Aspiriant LLC Makes New $661,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

June 18 at 7:10 AM | marketbeat.com

Tempus AI (NASDAQ:TEM) Shares Down 1.6% - Here's Why

June 17 at 2:35 PM | marketbeat.com

Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference

June 17 at 8:30 AM | businesswire.com

Rakuten Securities Inc. Boosts Stake in Tempus AI, Inc. (NASDAQ:TEM)

June 17 at 6:54 AM | marketbeat.com

Nancy Pelosi is up 130% on this stock since January

June 17 at 6:51 AM | finbold.com

Exchange Traded Concepts LLC Has $4.30 Million Stock Position in Tempus AI, Inc. (NASDAQ:TEM)

June 17 at 3:59 AM | marketbeat.com

TEMPUS AI SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM

June 16, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Quantum Stocks Skyrocket, Led by IonQ's NVIDIA Declaration
By Leo Miller | May 27, 2025
View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA Declaration
Why SailPoint May Cruise Past Cybersecurity Rivals in 2025
By Nathan Reiff | June 18, 2025
View Why SailPoint May Cruise Past Cybersecurity Rivals in 2025
D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?
By Nathan Reiff | May 28, 2025
View D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?

AET, CVS, RPRX, TEM, and GH Company Descriptions

Aetna NYSE:AET

Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.

CVS Health NYSE:CVS

$66.90 -0.19 (-0.28%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$66.80 -0.11 (-0.16%)

As of 07:30 AM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Guardant Health NASDAQ:GH

$50.57 +1.04 (+2.10%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$50.88 +0.31 (+0.60%)

As of 07:32 AM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Royalty Pharma NASDAQ:RPRX

$34.91 +0.35 (+1.01%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$34.78 -0.13 (-0.37%)

As of 07:00 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Tempus AI NASDAQ:TEM

$69.10 -1.01 (-1.44%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$69.32 +0.22 (+0.32%)

As of 07:38 AM Eastern

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AET, CVS, RPRX, TEM, and GH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AET, CVS, RPRX, TEM, and GH Earnings

Compare Dividends

Latest AET, CVS, RPRX, TEM, and GH Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AET, CVS, RPRX, TEM, and GH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AET, CVS, RPRX, TEM, and GH Company Descriptions

Aetna NYSE:AET

CVS Health NYSE:CVS

Guardant Health NASDAQ:GH

Royalty Pharma NASDAQ:RPRX

Tempus AI NASDAQ:TEM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools